ORIC Pharmaceuticals, Inc.

NasdaqGS ORIC

ORIC Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

ORIC Pharmaceuticals, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
  • ORIC Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
  • ORIC Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
  • ORIC Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00, a 0.00% change year over year.
  • ORIC Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -0.00.
Key data
Date Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE)
Market news
Loading...
NasdaqGS: ORIC

ORIC Pharmaceuticals, Inc.

CEO Dr. Jacob M. Chacko M.B.A., M.D.
IPO Date April 24, 2020
Location United States
Headquarters 240 East Grand Avenue
Employees 112
Sector Health Care
Industries
Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Similar companies

PEPG

PepGen Inc.

USD 2.72

-2.86%

IMRX

Immuneering Corporation

USD 1.95

-2.99%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

CELC

Celcuity Inc.

USD 10.53

-2.95%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

PHVS

Pharvaris N.V.

USD 16.00

-2.50%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

ELVN

Enliven Therapeutics, Inc.

USD 20.46

-7.29%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

HOWL

Werewolf Therapeutics, Inc.

USD 1.35

0.00%

SEER

Seer, Inc.

USD 2.29

-1.29%

StockViz Staff

January 16, 2025

Any question? Send us an email